NCT05306275View on ClinicalTrials.gov

A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

April 4, 2022

Primary Completion Date

September 27, 2022

Study Completion Date

September 27, 2022

Conditions
Healthy Participants
Interventions
DRUG

CSL312

Factor XIIa antagonist monoclonal antibody for subcutaneous use

Trial Locations (1)

92801

Anaheim Clinical Trials, LLC, Anaheim

Sponsors

Lead Sponsor

CSL Behring
All Listed Sponsors
lead

CSL Behring

INDUSTRY

NCT05306275 - A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects | Biotech Hunter | Biotech Hunter